Fang-Ju Lin1,2,3, Hung-Wei Lin1, Yunn-Fang Ho4,5,6. 1. Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, No. 33, Lin-Sen S. Rd., Taipei, 10050, Taiwan. 2. School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan. 3. Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan. 4. Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, No. 33, Lin-Sen S. Rd., Taipei, 10050, Taiwan. yfho@ntu.edu.tw. 5. School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan. yfho@ntu.edu.tw. 6. Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan. yfho@ntu.edu.tw.
Abstract
BACKGROUND: Statins possess neuroprotective effects. However, real-world evidence supporting their utility in post-stroke epilepsy (PSE) prevention is limited. OBJECTIVE: The association between statin use, including timing of prescribing (pre-stroke vs post-stroke), type (lipophilicity, intensity of therapy) and dose intensity, and risk of developing PSE were investigated by studying Taiwanese health claims (2003-2013). METHODS: Patients with new-onset ischaemic stroke were identified. The main outcome was a diagnosis of epilepsy after ischaemic stroke. According to pre-stroke statin use, groups of current users, former users, and non-users were compared using ANOVA. An extended Cox regression model was utilized to estimate the hazard ratio (HR) of PSE, with post-stroke statin use and certain comedications as time-dependent variables. Serial sensitivity analyses were performed to ensure study robustness. RESULTS: Of the 20,858 ischaemic stroke patients, 954 (4.6%) developed PSE. Post-stroke statin use (adjusted HR (aHR) 0.55; 95% confidence interval 0.46-0.67, p < 0.001), but not pre-stroke statin use was associated with a significantly reduced risk of developing PSE. A dose-response correlation was also observed between PSE risk reduction and quartiles of the statin cumulative defined daily dose (cDDD) (aHR 0.84, 0.67, 0.53, and 0.50 for the lowest, second, third, and highest quartiles of cDDD, respectively). Risk predictors and protectors against PSE were also characterized. CONCLUSION: The post-stroke use of statins after ischaemic stroke was associated with PSE risk reduction in a cDDD-dependent manner. Further clinical studies on the potential applications of statins for PSE prophylaxis, particularly among at-risk patients, are warranted.
BACKGROUND: Statins possess neuroprotective effects. However, real-world evidence supporting their utility in post-stroke epilepsy (PSE) prevention is limited. OBJECTIVE: The association between statin use, including timing of prescribing (pre-stroke vs post-stroke), type (lipophilicity, intensity of therapy) and dose intensity, and risk of developing PSE were investigated by studying Taiwanese health claims (2003-2013). METHODS:Patients with new-onset ischaemic stroke were identified. The main outcome was a diagnosis of epilepsy after ischaemic stroke. According to pre-stroke statin use, groups of current users, former users, and non-users were compared using ANOVA. An extended Cox regression model was utilized to estimate the hazard ratio (HR) of PSE, with post-stroke statin use and certain comedications as time-dependent variables. Serial sensitivity analyses were performed to ensure study robustness. RESULTS: Of the 20,858 ischaemic strokepatients, 954 (4.6%) developed PSE. Post-stroke statin use (adjusted HR (aHR) 0.55; 95% confidence interval 0.46-0.67, p < 0.001), but not pre-stroke statin use was associated with a significantly reduced risk of developing PSE. A dose-response correlation was also observed between PSE risk reduction and quartiles of the statin cumulative defined daily dose (cDDD) (aHR 0.84, 0.67, 0.53, and 0.50 for the lowest, second, third, and highest quartiles of cDDD, respectively). Risk predictors and protectors against PSE were also characterized. CONCLUSION: The post-stroke use of statins after ischaemic stroke was associated with PSE risk reduction in a cDDD-dependent manner. Further clinical studies on the potential applications of statins for PSE prophylaxis, particularly among at-risk patients, are warranted.
Authors: F B Seker; U Kilic; B Caglayan; M S Ethemoglu; A B Caglayan; N Ekimci; S Demirci; A Dogan; S Oztezcan; F Sahin; B Yilmaz; E Kilic Journal: Neuroscience Date: 2014-10-19 Impact factor: 3.590
Authors: Mary Jo V Pugh; Janice E Knoefel; Eric M Mortensen; Megan E Amuan; Dan R Berlowitz; Anne C Van Cott Journal: J Am Geriatr Soc Date: 2009-02 Impact factor: 5.562
Authors: Amelia J McFarland; Shailendra Anoopkumar-Dukie; Devinder S Arora; Gary D Grant; Catherine M McDermott; Anthony V Perkins; Andrew K Davey Journal: Int J Mol Sci Date: 2014-11-10 Impact factor: 5.923
Authors: Neil S N Graham; Siobhan Crichton; Michael Koutroumanidis; Charles D A Wolfe; Anthony G Rudd Journal: Stroke Date: 2013-01-31 Impact factor: 7.914